Glucagon Administration for Hypoglycemia

Introduction to Glucagon Administration

• The American Diabetes Association recommends that for severe hypoglycemia, glucagon should be administered intramuscularly (IM), subcutaneously (SC), or intranasally, with newer intranasal and ready-to-inject formulations preferred over traditional reconstitution kits due to their ease of administration and more rapid correction of hypoglycemia 1

Preferred Formulations and Administration

• The American Association of Clinical Endocrinologists suggests that intranasal and ready-to-inject glucagon preparations are now preferred over traditional reconstitution kits because they are easier to administer by untrained caregivers, resulting in more rapid correction of hypoglycemia 1
• The Endocrine Society recommends that family members, roommates, school personnel, childcare professionals, correctional staff, and coworkers should be trained on glucagon administration, including where the glucagon product is kept, when to administer it, how to administer it, and explicit education to never administer insulin to individuals experiencing hypoglycemia 1

Patient Selection for Glucagon Prescription

• The American College of Endocrinology recommends that all individuals treated with insulin—even basal-only regimens—should be prescribed glucagon 1, 2
• The European Association for the Study of Diabetes suggests that glucagon may also be considered for persons taking sulfonylureas who meet criteria for high hypoglycemia risk 2, 3

Storage and Replacement

• The International Diabetes Federation recommends that glucagon products should be replaced when they reach their expiration date and stored according to specific product instructions to ensure safe and effective use 1

Glucagon Administration Guidelines

Formulations and Administration

• Multiple formulations of glucagon are available, including traditional reconstitution kits, pre-filled pens/syringes, and intranasal glucagon, according to the American Diabetes Association 4
• Blood glucose should be monitored after glucagon administration to ensure adequate response, as recommended by the American Diabetes Association 4

Expected Response and Monitoring

• Glucagon typically increases blood glucose levels within 5-15 minutes after administration, with a moderate strength of evidence 5
• The American Diabetes Association recommends that blood glucose be monitored after administration to ensure adequate response 4

Important Clinical Considerations

• The American College of Clinical Endocrinologists recommends that glucagon be prescribed for all patients at increased risk for clinically significant hypoglycemia, with a high strength of evidence 5
• Caregivers, family members, and others in close contact with the patient should be trained on glucagon administration, as recommended by the American College of Clinical Endocrinologists 5

Storage and Replacement

• The American Diabetes Association recommends that care be taken to replace glucagon products when they reach their expiration date, with a moderate strength of evidence 5
• Glucagon products should be stored according to specific product instructions to ensure safe and effective use, as recommended by the American Diabetes Association 5

Glucagon Administration and Management

Expected Side Effects and Contraindications

• The American Heart Association, as published in Circulation, notes that nausea and vomiting are common side effects of glucagon, particularly with higher doses, and that the airway must be protected before glucagon administration in patients with central nervous system depression 6

Maximum Dose of Intramuscular Glucagon for Hypoglycemia

Standard Dosing Protocol

• The American Diabetes Association recommends a maximum dose of 1 mg (1000 mcg) of intramuscular glucagon for adults and children, regardless of age or weight, for the treatment of hypoglycemia 7, 8
• The established intramuscular dose for severe hypoglycemia is 0.5-1.0 mg IM for adults and children, as recommended by the American Association of Clinical Endocrinologists 7, 8

Critical Clinical Considerations

• The Society of Critical Care Medicine recommends IV dextrose over glucagon in the ICU setting due to faster response time when venous access is available 9

When Glucagon May Be Insufficient

• If the patient does not respond adequately to the initial 1 mg IM dose, the American Diabetes Association recommends switching to IV dextrose administration, with an initial dose of 20-40 mL of 50% glucose solution 7, 8
• The slower response with glucagon makes it less ideal than IV dextrose when venous access is available, as noted by the Society of Critical Care Medicine 9

Maximum Glucagon Dosage for Hypoglycemia Without IV Access in EMS Setting

Standard Dosing Protocol

• The American Heart Association recommends administering 1 mg (1000 mcg) of glucagon intramuscularly or subcutaneously for adults and children weighing more than 25 kg (or age ≥6 years), and 0.5 mg (500 mcg) for children weighing less than 25 kg (or age <6 years), with a strength of evidence not specified 10

Critical Clinical Considerations

• The American Heart Association suggests that airway protection is mandatory before glucagon administration in patients with altered mental status, and nausea and vomiting are common side effects, particularly with higher doses, with a strength of evidence not specified 10
• The European Association for the Study of Diabetes recommends providing oral carbohydrates immediately to restore liver glycogen and prevent secondary hypoglycemia, and giving starchy or protein-rich foods after the patient responds and can swallow safely, with a strength of evidence not specified 11